These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

316 related items for PubMed ID: 18831725

  • 1. Luminal B breast tumors are not HER2 positive.
    Bhargava R, Dabbs DJ.
    Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
    [No Abstract] [Full Text] [Related]

  • 2. HER2 as a prognostic factor in breast cancer.
    Ménard S, Fortis S, Castiglioni F, Agresti R, Balsari A.
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Analysis of chromosomal aberrations in breast cancer by comparative genomic hybridization (CGH). Correlation with histoprognostic variables and c-erbB-2 immunoexpression.
    Malamou-Mitsi VD, Syrrou M, Georgiou I, Pagoulatos G, Agnantis NJ.
    J Exp Clin Cancer Res; 1999 Sep; 18(3):357-61. PubMed ID: 10606182
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Current status of HER2 testing: caught between a rock and a hard place.
    Schnitt SJ, Jacobs TW.
    Am J Clin Pathol; 2001 Dec; 116(6):806-10. PubMed ID: 11764067
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. HER2/neu amplification in breast cancer: stratification by tumor type and grade.
    Hoff ER, Tubbs RR, Myles JL, Procop GW.
    Am J Clin Pathol; 2002 Jun; 117(6):916-21. PubMed ID: 12047143
    [Abstract] [Full Text] [Related]

  • 15. Diagnostic accuracy and prognostic value of core biopsy in the management of breast cancer: a series of 542 patients.
    Richter-Ehrenstein C, Müller S, Noske A, Schneider A.
    Int J Surg Pathol; 2009 Aug; 17(4):323-6. PubMed ID: 19029173
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H, Ando Y, Ichihara S, Toyoshima S, Nakamura T, Karamatsu S, Ito Y, Yamashita H, Toyama T, Omoto Y, Fujii Y, Mitsuyama S, Kobayashi S.
    Breast Cancer; 2001 Aug; 8(2):98-104. PubMed ID: 11342981
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular evidence for progression of microglandular adenosis (MGA) to invasive carcinoma.
    Shin SJ, Simpson PT, Da Silva L, Jayanthan J, Reid L, Lakhani SR, Rosen PP.
    Am J Surg Pathol; 2009 Apr; 33(4):496-504. PubMed ID: 19047897
    [Abstract] [Full Text] [Related]

  • 19. Selective reduction of estrogen receptor (ER) positive breast cancer occurrence by estrogen receptor modulators supports etiological distinction between ER positive and ER negative breast cancers.
    Kurbel S.
    Med Hypotheses; 2005 Apr; 64(6):1182-7. PubMed ID: 15823713
    [Abstract] [Full Text] [Related]

  • 20. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
    Czerwenka KF, Zeillinger R, Kury F, Manavi M, Speiser P, Peschke M, Steinhart U, Hosmann JW, Kubista E.
    Gynakol Rundsch; 1991 Apr; 31 Suppl 2():378-9. PubMed ID: 1686430
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.